Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features

Jae-Lyun Lee,Inkeun Park,Kwonoh Park,Seong Joon Park,Yongcheol Ahn,Jin-Hee Ahn,Tae-Won Kim,Shin Ahn,Cheryn Song,Jun Hyuk Hong,Choung-Soo Kim,Hanjong Ahn

Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features

2012

Jae-Lyun Lee
Inkeun Park
Kwonoh Park
Seong Joon Park
Yongcheol Ahn
Jin-Hee Ahn
Tae-Won Kim
Shin Ahn
Cheryn Song
Jun Hyuk Hong
Choung-Soo Kim
Hanjong Ahn

Background Temsirolimus is a standard of care in patients with metastatic renal cell carcinoma (mRCC) with poor risk factors. The role of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) remains poorly defined in this setting.

Keywords:

Temsirolimus
Pazopanib
Oncology
Tyrosine kinase
Renal cell carcinoma
Vascular Endothelial Growth Factor Receptor
Sorafenib
Biology
Sunitinib
Diabetes mellitus
Internal medicine
Hematology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations